Anti-Lymphotoxin - Pipeline Insight Report 2018 Featuring Roche, Zydus, Amgen & Biogen Idec - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Aug 24, 2018--The “Anti-Lymphotoxin -Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
‘Anti-Lymphotoxin - Pipeline Insight, 2018’ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-Lymphotoxin development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Descriptive coverage of pipeline development activities for Anti-Lymphotoxin - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. Anti-Lymphotoxin - Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. Anti-Lymphotoxin Pipeline Products in Clinical Stages
6. Anti-Lymphotoxin Pipeline Products in Non-clinical Stages
7. Therapeutic Assessment: Active Products
8. Inactive Pipeline Products
Companies MentionedRoche Zydus Amgen Biogen Idec
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/c63ltv/antilymphotoxin?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180824005411/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Lymphoma Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/24/2018 02:57 PM/DISC: 08/24/2018 02:57 PM